Can a single injection of SYH2082 help tackle obesity? a first-in-human trial puts safety to the test.

NCT ID NCT07736404

Ongoing Disease control Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This Phase 1 trial tests whether a single dose of an experimental drug called SYH2082 is safe and tolerable in healthy adults aged 18 to 55 who are overweight or have obesity. Participants receive either the drug or a placebo injection, and researchers monitor for side effects and how the drug moves through the body. The goal is to gather early safety data before moving to larger studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental injection called SYH2082
What this could lead to: If safe, this could lead to a new treatment option for weight loss in people with overweight or obesity.
What could go wrong: This is an early Phase 1 trial with only 50 healthy participants, so safety and effectiveness are not yet known. Side effects may occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT OR OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVERWEIGHT OR OBESITY

Contacts and locations

Locations

The Affiliated Hospital of Nanjing University Medical School

Nanjing, Jiangsu, 210008, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.